Fed. Circ. Upholds AstraZeneca's Crestor Patent
AstraZeneca said in a statement that the ruling means that none of the eight companies that sought to market generic versions of Crestor, which were consolidated as defendants, will be able to do so until the patent expires in 2016. Crestor had sales of $6.6 billion in 2011, according to the company.
To view the full article, register now.